文献速递浆细胞疾病

新诊断多发性骨髓瘤的结局预测:1905例试验患者分子特征的荟萃分析

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
PubMed 文献 · Leukemia · 2017-06-06

该研究对NCRI Myeloma XI试验中1036例患者的拷贝数改变(CNA)和易位进行检测,并与MRC Myeloma IX试验数据做荟萃分析,合计1905例新诊断多发性骨髓瘤(NDMM)患者。研究证实t(4;14)、t(14;16)、t(14;20)、del(17p)和gain(1q21)与不良预后相关,并定义了「双打击」及不同超二倍体亚组。

要点

  • t(4;14)、t(14;16)、t(14;20)、del(17p)和gain(1q21)与新诊断多发性骨髓瘤总生存期(OS)的不良预后相关。
  • 「双打击」患者(至少两种不良病变共存)预后尤其差,全部患者HR为2.67。
  • 综合CNA和易位分析可识别可能早期复发的多发性骨髓瘤患者,以帮助分层治疗。

核心结论

  • t(4;14)、t(14;16)、t(14;20)、del(17p)和gain(1q21)与新诊断多发性骨髓瘤的不良预后相关,双打击患者预后尤其差,综合多基因病变分析可识别可能早期复发的患者以帮助分层治疗。

研究设计与样本

  • 研究对NCRI Myeloma XI试验中1036例患者的CNA和易位进行检测,并与MRC Myeloma IX试验数据做荟萃分析,合计1905例新诊断多发性骨髓瘤患者。

主要发现

  • t(4;14)、t(14;16)、t(14;20)、del(17p)和gain(1q21)与OS不良预后相关,HR分别为1.60(P=4.77×10-7)、1.74(P=0.0005)、1.90(P=0.0089)、2.10(P=8.86×10-14)和1.68(P=2.18×10-14)。
  • 双打击患者(至少两种不良病变共存)全部患者OS的HR为2.67(P=8.13×10-27),强化治疗患者OS的HR为3.19(P=1.23×10-18)。
  • Myeloma XI中t(4;14)与BIRC2/BIRC3缺失(包括纯合缺失)强相关(P=8.7×10-15)。
  • 超二倍体多发性骨髓瘤可分为gain(1q21)伴CCND2过表达(P<0.0001)或gain(11q25)伴CCND1过表达(P<0.0001)的不同亚组。

临床怎么用

  • 作者认为,对多个基因病变进行检测可识别可能早期复发的多发性骨髓瘤患者,从而帮助进行治疗分层。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) and translocations in 1036 patients from the NCRI Myeloma XI trial and linked these to overall survival (OS) and progression-free survival. Through a meta-anlysis of these data with data from MRC Myeloma IX trial, totalling 1905 newly diagnosed MM patients (NDMM), we confirm the association of t(4;14), t(14;16), t(14;20), del(17p) and gain(1q21) with poor prognosis with hazard ratios (HRs) for OS of 1.60 (P=4.77 × 10-7), 1.74 (P=0.0005), 1.90 (P=0.0089), 2.10 (P=8.86 × 10-14) and 1.68 (P=2.18 × 10-14), respectively. Patients with 'double-hit' defined by co-occurrence of at least two adverse lesions have an especially poor prognosis with HRs for OS of 2.67 (P=8.13 × 10-27) for all patients and 3.19 (P=1.23 × 10-18) for intensively treated patients. Using comprehensive CNA and translocation profiling in Myeloma XI we also demonstrate a strong association between t(4;14) and BIRC2/BIRC3 deletion (P=8.7 × 10-15), including homozygous deletion. Finally, we define distinct sub-groups of hyperdiploid MM, with either gain(1q21) and CCND2 overexpression (P<0.0001) or gain(11q25) and CCND1 overexpression (P<0.0001). Profiling multiple genetic lesions can identify MM patients likely to relapse early allowing stratification of treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2017. PMID: 28584253. doi:10.1038/leu.2017.179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。